{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T18:10:19Z","timestamp":1773339019473,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,1,8]],"date-time":"2011-01-08T00:00:00Z","timestamp":1294444800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1007\/s12032-010-9781-z","type":"journal-article","created":{"date-parts":[[2011,1,7]],"date-time":"2011-01-07T14:27:35Z","timestamp":1294410455000},"page":"219-226","source":"Crossref","is-referenced-by-count":11,"title":["BCR-ABL isoforms associated with intrinsic or acquired resistance to imatinib: more heterogeneous than just ABL kinase domain point mutations?"],"prefix":"10.1007","volume":"29","author":[{"given":"Franz X.","family":"Gruber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tuija","family":"Lund\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rasmus","family":"Goll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Silye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingvild","family":"Mikkola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ole Petter","family":"Rekvig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sakari","family":"Knuutila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kari","family":"Remes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Gedde-Dahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimmo","family":"Porkka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Hjorth-Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,1,8]]},"reference":[{"key":"9781_CR1","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1100\/tsw.2006.184","volume":"6","author":"MR Burgess","year":"2006","unstructured":"Burgess MR, Sawyers CL. Treating imatinib-resistant leukemia: the next generation targeted therapies. ScientificWorldJournal. 2006;6:918\u201330.","journal-title":"ScientificWorldJournal"},{"key":"9781_CR2","first-page":"534","volume":"90","author":"G Martinelli","year":"2005","unstructured":"Martinelli G, Soverini S, Rosti G, Cilloni D, Baccarani M. New tyrosine kinase inhibitors in chronic myeloid leukemia. Haematologica. 2005;90:534\u201341.","journal-title":"Haematologica"},{"key":"9781_CR3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.seminhematol.2006.12.002","volume":"44","author":"A Hochhaus","year":"2007","unstructured":"Hochhaus A, Erben P, Ernst T, Mueller M. Resistance to targeted therapy in chronic myelogenous leukemia. Semin Hematol. 2007;44:15\u201324.","journal-title":"Semin Hematol"},{"key":"9781_CR4","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","volume":"16","author":"A Hochhaus","year":"2002","unstructured":"Hochhaus A, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 2002;16:2190\u20136.","journal-title":"Leukemia"},{"key":"9781_CR5","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/sj.leu.2402889","volume":"17","author":"N Bubnoff Von","year":"2003","unstructured":"Von Bubnoff N, Peschel C, Duyster J. Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back. Leukemia. 2003;17:829\u201338.","journal-title":"Leukemia"},{"key":"9781_CR6","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","volume":"102","author":"S Branford","year":"2003","unstructured":"Branford S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 2003;102:276\u201383.","journal-title":"Blood"},{"key":"9781_CR7","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/sj.leu.2404236","volume":"20","author":"FE Nicolini","year":"2006","unstructured":"Nicolini FE, et al. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). Leukemia. 2006;20:1061\u20136.","journal-title":"Leukemia"},{"key":"9781_CR8","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1200\/JCO.2005.05.531","volume":"23","author":"S Soverini","year":"2005","unstructured":"Soverini S, et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA working party on chronic myeloid leukemia. J Clin Oncol. 2005;23:4100\u20139.","journal-title":"J Clin Oncol"},{"key":"9781_CR9","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","volume":"20","author":"E Jabbour","year":"2006","unstructured":"Jabbour E, et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia. 2006;20:1767\u201373.","journal-title":"Leukemia"},{"key":"9781_CR10","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293:876\u201380.","journal-title":"Science"},{"key":"9781_CR11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","volume":"2","author":"NP Shah","year":"2002","unstructured":"Shah NP, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002;2:117\u201325.","journal-title":"Cancer Cell"},{"key":"9781_CR12","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nrd2324","volume":"6","author":"A Quintas-Cardama","year":"2002","unstructured":"Quintas-Cardama A, Kantarjian H, Cortes J. Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov. 2002;6:834\u201348.","journal-title":"Nat Rev Drug Discov"},{"key":"9781_CR13","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1038\/sj.leu.2404400","volume":"20","author":"FX Gruber","year":"2006","unstructured":"Gruber FX, Hjorth-Hansen H, Mikkola I, Stenke L, Johansen T. A novel Bcr-Abl splice isoform is associated with the L248\u00a0V mutation in CML patients with acquired resistance to imatinib. Leukemia. 2006;20:2057\u201360.","journal-title":"Leukemia"},{"key":"9781_CR14","doi-asserted-by":"crossref","unstructured":"Khorashad JS, et al. Abnormally small BCR-ABL transcripts in CML patients before and during imatinib treatment. In: The American Society of Hematology 2006 Annual Meeting (ed. by Abstract). Blood, 2006; 108, 2153\u00a0p.","DOI":"10.1182\/blood.V108.11.2153.2153"},{"key":"9781_CR15","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1158\/0008-5472.CAN-06-3737","volume":"67","author":"G Volpe","year":"2007","unstructured":"Volpe G, et al. Alternative BCR\/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches. Cancer Res. 2007;67:5300\u20137.","journal-title":"Cancer Res"},{"key":"9781_CR16","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/leu.2008.65","volume":"22","author":"DW Sherbenou","year":"2008","unstructured":"Sherbenou DW, et al. Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia. Leukemia. 2008;22:1184\u201390.","journal-title":"Leukemia"},{"key":"9781_CR17","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","volume":"108","author":"M Baccarani","year":"2006","unstructured":"Baccarani M, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809\u201320.","journal-title":"Blood"},{"key":"9781_CR18","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","volume":"17","author":"J Gabert","year":"2003","unstructured":"Gabert J, et al. Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia\u2014a Europe against cancer program. Leukemia. 2003;17:2318\u201357.","journal-title":"Leukemia"},{"key":"9781_CR19","first-page":"186","volume":"8","author":"NC Cross","year":"1994","unstructured":"Cross NC, Melo JV, Feng L, Goldman JM. An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia. 1994;8:186\u20139.","journal-title":"Leukemia"},{"key":"9781_CR20","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1038\/sj.leu.2403983","volume":"19","author":"FX Gruber","year":"2005","unstructured":"Gruber FX, et al. Selecting and deselecting imatinib-resistant clones: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL. Leukemia. 2005;19:2159\u201365.","journal-title":"Leukemia"},{"key":"9781_CR21","first-page":"93","volume":"125","author":"S Branford","year":"2006","unstructured":"Branford S, Hughes T. Detection of BCR-ABL mutations and resistance to imatinib mesylate. Methods Mol Med. 2006;125:93\u2013106.","journal-title":"Methods Mol Med"},{"key":"9781_CR22","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3324\/haematol.11993","volume":"93","author":"T Ernst","year":"2008","unstructured":"Ernst T, et al. Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib. Haematologica. 2008;93:186\u201392.","journal-title":"Haematologica"},{"key":"9781_CR23","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood.V99.9.3472","volume":"99","author":"S Branford","year":"2002","unstructured":"Branford S, et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR\/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood. 2002;99:3472\u20135.","journal-title":"Blood"},{"key":"9781_CR24","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1373\/clinchem.2004.031112","volume":"50","author":"S Soverini","year":"2004","unstructured":"Soverini S, et al. Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib. Clin Chem. 2004;50:1205\u201313.","journal-title":"Clin Chem"},{"key":"9781_CR25","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.leukres.2007.04.018","volume":"32","author":"RP Curvo","year":"2008","unstructured":"Curvo RP, et al. A recurrent splicing variant without c-ABL Exon 7 in Imatinib-resistant patients. Leuk Res. 2008;32:508\u201310.","journal-title":"Leuk Res"},{"key":"9781_CR26","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3324\/haematol.10822","volume":"92","author":"S Soverini","year":"2007","unstructured":"Soverini S, et al. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica. 2007;92:401\u20134.","journal-title":"Haematologica"},{"key":"9781_CR27","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/sj.leu.2404490","volume":"21","author":"FE Nicolini","year":"2007","unstructured":"Nicolini FE, Corm S, Le QH, Roche-Lestienne C, Preudhomme C. The prognosis impact of BCR-ABL P-loop mutations: worse or not worse? Leukemia. 2007;21:193\u20134.","journal-title":"Leukemia"},{"key":"9781_CR28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00109-007-0241-y","volume":"86","author":"I Roeder","year":"2008","unstructured":"Roeder I, Glauche I. Pathogenesis, treatment effects, and resistance dynamics in chronic myeloid leukemia\u2014insights from mathematical model analyses. J Mol Med. 2008;86:17\u201327.","journal-title":"J Mol Med"},{"key":"9781_CR29","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/nm1487","volume":"2","author":"I Roeder","year":"2006","unstructured":"Roeder I, et al. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat Med. 2006;2:1181\u20134.","journal-title":"Nat Med"},{"key":"9781_CR30","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1182\/blood-2004-03-1134","volume":"104","author":"S Branford","year":"2004","unstructured":"Branford S, et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood. 2004;104:2926\u201332.","journal-title":"Blood"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-010-9781-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-010-9781-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-010-9781-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T10:57:02Z","timestamp":1592218622000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-010-9781-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,8]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["9781"],"URL":"https:\/\/doi.org\/10.1007\/s12032-010-9781-z","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,8]]}}}